Detection of MEN1 resistance mutations in cell-free DNA from acute leukemia patients treated with menin inhibitors.
Blood tests can now detect when leukemia patients develop resistance to cutting-edge menin inhibitor drugs, enabling faster treatment adjustments without invasive procedures.
This MSK study demonstrates that cfDNA can detect MEN1 resistance mutations in patients with acute leukemia undergoing menin inhibitor therapy, enabling real-time monitoring of acquired resistance. The finding establishes a non-invasive surveillance framework for a cutting-edge drug class (menin inhibitors) with rapidly expanding clinical use in KMT2A/NPM1-mutated leukemia.
What the study was
- Study design
- Retrospective/prospective cohort — cfDNA monitoring in menin inhibitor-treated acute leukemia patients (Memorial Sloan Kettering)
- Population
- Pediatric and adult patients with acute leukemia (AML/ALL with KMT2A or NPM1 mutations) treated with menin inhibitors at MSK
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- Blood Cancer Journal
Why it surfaced
cfDNA monitoring of MEN1 resistance in menin inhibitor-treated acute leukemia is a highly clinically actionable finding from a top center (MSK) in a premier journal (Blood Cancer J). Menin inhibitors are a newly approved drug class (revumenib/ziftomenib) and resistance mechanisms are an urgent clinical need. The liquid biopsy approach provides real-time surveillance without repeat bone marrow biopsy.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.